Areas of interest (AOI) & competitive research grants
We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.
| Therapeutic Area and / or Compound | AOIs Posted on BMS.com | Pre-Concept Submission Period | |
| Start Date | End date | ||
| Neuropsychiatry - KarXT (Xanomeline/trospium) | Sept 27, 2024 | Oct 28, 2024 | Jan 3, 2025 |
KarXT ISR Areas of Interest – RFP #1 2024
- Investigation of disease states where the pharmacology of KarXT matches with the hypothesized underlying biology of psychiatric illnesses.
- Understanding the impact of KarXT on the following in patients with SCZ:
- Overall functioning
- Cognitive functioning
- Predominant negative symptoms
- Additional measures of response (e.g., patient satisfaction, other Patient-Reported Outcomes)
- Additional areas of interest for the approved indication (schizophrenia)
- KarXT in Early Psychosis
- Real-world use and efficacy/safety (Clinical, HEOR or both)
- Burden of disease
- Costs related to the disease and its treatments
- The safety and efficacy of switching to KarXT from other antipsychotics
- Novel outcomes related to treatment with KarXT
- Pharmacogenetic predictors of KarXT response
- Use of AI to determine predictors of response (existing or new data)
- Treatment-resistant schizophrenia or treatment-experienced patients
- Efficacy in patients with schizophrenia and medical or psychiatric comorbidities (eg., substance-use disorder)
- Imaging studies to further the understanding of M1/M4 muscarinic receptors in the disease state or MOA of KarXT
- Non-clinical studies furthering the understanding of the role of KarXT in schizophrenia
Out of Scope
- Indications and/or patient populations where KarXT has been or is being evaluated
- Relapse prevention in patients with schizophrenia
- Adolescent schizophrenia
- Autism spectrum disorder
- Bipolar 1 disorder
- Alzheimer’s disorder (psychosis, agitation)
- Populations requiring treatment with centrally acting anticholinergic agents
- Patients with medical conditions that are not compatible with KarXT use (eg, urinary retention, gastric retention, narrow-angle glaucoma)
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.
- If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here
- If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
- If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
- If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here